Trial Profile
Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Nov 2021
Price :
$35
*
At a glance
- Drugs Amphotericin B liposomal (Primary)
- Indications Allergic bronchopulmonary aspergillosis
- Focus Therapeutic Use
- Acronyms NEBULAMB
- 11 Nov 2021 Primary endpoint has not been met. (Occurrence of first severe clinical exacerbation), as per Results published in the European Respiratory Journal
- 11 Nov 2021 Results published in the European Respiratory Journal
- 08 Jun 2020 Status changed from active, no longer recruiting to completed.